{
  "id": 20734112,
  "title": "New alarm over China controlling drug supply chains",
  "url": "https://urgent.news/2026/11/19/new-alarm-over-china-controlling-drug-supply-chains",
  "topic": "world",
  "section": "World",
  "published": "2026-11-19T10:30:05.000Z",
  "source": {
    "name": "Axios",
    "slug": "axios",
    "url": "https://www.axios.com/2026/11/19/china-biotech-policy-warning"
  },
  "original_language": "en",
  "account": "A new analysis from the National Security Commission on Emerging Biotechnology warns that China is intensifying its efforts to control the entire drug supply chain, putting the United States at risk of losing access to future lifesaving treatments. The commission's analysis examines 57 deals between Western drug giants and Chinese biotechnology firms from the start of 2023 through last month. These deals involve licensing agreements that transfer U.S. capital and expertise to China, giving Beijing more control over critical pharmaceutical technologies.\n\nThe commission fears that this trend could erode biotech research and development (R&D) in the U.S. and create a scenario where China corners a market, establishing a stranglehold on supplies of key products and ingredients. While cash-based deals that bring royalties and milestone payments are still permitted, equity investments in Chinese firms are prohibited. The commission calls for policymakers to act now to out-innovate strategic competitors before it's too late.",
  "summary": "China is intensifying efforts to control the entire drug supply chain, putting the U.S. at risk of being cut off from future lifesaving treatments, the National Security Commission on Emerging Biotechnology warns in a new analysis out Thursday. Why it matters: Western drug giants have invested huge sums in Chinese biotechs to boost their product pipelines. But sharing capital and expertise could…",
  "key_points": [
    "China intensifies control over drug supply chain, threatening U.S. access to lifesaving treatments",
    "Commission urges policymakers to act now to maintain U.S. innovation in biotech R&D"
  ],
  "editors_take": "Increasing licensing agreements transfer American capital and expertise to Beijing, threatening to erode domestic research capabilities and leave the United States vulnerable to Chinese control over critical pharmaceutical supplies.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}